Why a US Patient Chose China for CAR-T: A Documented DLBCL Case Study
A clinical journey, not a testimonial. This case follows one patient's path through relapsed diffuse large B-cell lymphoma, three prior lines of therapy, and CD19-directed CAR-T cell therapy coordinated in Beijing.
Case At a Glance
Background: Why This Patient Was Looking Beyond the US
Diffuse large B-cell lymphoma is the most common aggressive non-Hodgkin lymphoma, and most patients respond well to first-line chemoimmunotherapy. But about 30% to 40% of patients with newly diagnosed DLBCL experience relapse, and roughly 10% are refractory to standard R-CHOP from the start. For patients who relapse early or fail to respond to salvage chemotherapy, the outlook without further intervention is poor — historically, relapsed/refractory DLBCL patients who are ineligible for stem cell transplant have an expected median overall survival of roughly 6 months, with a 2-year survival of only about 20%.
This is precisely the population CD19-directed CAR-T therapy was developed for. CAR-T therapy is now a fixture in the treatment algorithm for DLBCL patients who have received two or more prior lines of therapy, with three FDA-approved CD19 CAR-T products currently available in the US: axicabtagene ciloleucel (axi-cel, Yescarta), tisagenlecleucel (tisa-cel, Kymriah), and lisocabtagene maraleucel (liso-cel, Breyanzi).
In this patient's case, the decision to seek treatment in Beijing was driven by a combination of factors: a 14-week manufacturing waitlist at the nearest US CAR-T center, an insurance prior-authorization denial that was still under appeal, and rapidly progressing disease after the third line of therapy. The patient's home oncologist supported exploring faster access through a partner center in Beijing that could complete leukapheresis within 10 days of referral.
Clinical Timeline
Initial Diagnosis & First-Line Therapy
Diagnosed with Stage IV DLBCL (Ann Arbor staging), non-GCB subtype, IPI score 4 (high-intermediate risk). Initiated standard first-line R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6 cycles. Achieved partial response (PR) per Lugano criteria at end-of-treatment PET-CT.
First Relapse & Second-Line Therapy
PET-CT confirmed disease progression 6 months after completing R-CHOP. Salvage therapy with R-DHAP (rituximab, dexamethasone, high-dose cytarabine, cisplatin) for 2 cycles yielded stable disease but no meaningful response. Patient was evaluated for autologous stem cell transplant but deemed transplant-ineligible due to age-related cardiac comorbidities (mild diastolic dysfunction).
Second Relapse & Third-Line Therapy
Repeat PET-CT showed new hypermetabolic lymph nodes in the retroperitoneum and left supraclavicular region. Third-line therapy with polatuzumab vedotin + bendamustine + rituximab (Pola-BR) for 2 cycles achieved minimal response. At this point, the US treatment algorithm would typically consider CAR-T as standard third-line therapy, but access barriers prompted exploration of international options.
Referral & Pre-Treatment Workup in Beijing
First contact with the Beijing treatment center via CancerCareE coordination. Repeat staging performed: PET-CT confirmed Deauville 5 disease, bone marrow biopsy negative for involvement, LVEF 55% (adequate), infectious disease screening negative (HBV, HCV, HIV, CMV, EBV all negative). ECOG confirmed at 1. Patient cleared for CAR-T eligibility.
Leukapheresis
Peripheral blood mononuclear cells (PBMCs) collected via standard leukapheresis. T-cell yield: 2.1 × 10⁹ cells, viability 94%. Product shipped to GMP manufacturing facility. Manufacturing of CD19-directed CAR-T product began same day.
Bridging Therapy
Low-dose cyclophosphamide (500mg/m²) administered as bridging therapy to control disease while CAR-T product was manufactured. Patient tolerated well with mild fatigue. PET-CT at day 10 of bridging showed stable disease without progression.
Lymphodepleting Conditioning Chemotherapy
Standard fludarabine (30 mg/m²/day) + cyclophosphamide (500 mg/m²/day) administered over 3 days. Patient tolerated conditioning well with expected mild nausea (managed with ondansetron) and fatigue. No febrile neutropenia during conditioning.
CAR-T Infusion
CD19-directed CAR-T product infused intravenously over 20 minutes. Total dose: 2 × 10⁶ CAR+ T cells per kg body weight. Product characteristics: CAR+ purity 68%, CD4/CD8 ratio 1.2, viability 92%. Infusion well-tolerated with no immediate reactions. Patient admitted to step-down unit for close monitoring.
What Happened After Infusion: Monitoring and Toxicity Management
CAR-T therapy carries a well-characterized toxicity profile that any documented case study needs to report honestly, regardless of outcome. In real-world series of CD19 CAR-T for relapsed/refractory DLBCL, cytokine release syndrome (CRS) occurred in 89% of patients, with 95% of cases being grade 1 or 2, and immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 17% of patients, with the large majority being mild.
| Day Post-Infusion | Event | Grade | Management |
|---|---|---|---|
| Day 3 | Fever onset (38.9°C), mild hypotension | CRS Grade 2 | Tocilizumab 8 mg/kg IV × 1 dose, IV fluids, antipyretics |
| Day 4 | Fever resolved, BP normalized | Resolved | Continued monitoring in step-down unit |
| Day 5 | Mild fatigue, no neurologic symptoms | ICANS Grade 0 | Supportive care, oral hydration |
| Day 6 | ANC nadir 400/μL, afebrile | Neutropenia Grade 3 | G-CSF initiated, continued monitoring |
| Day 8 | ANC recovering, discharged to recovery apartment | Stable | Outpatient follow-up arranged, daily labs continued |
Toxicity Context
This patient's CRS course (Grade 2, resolved with single-dose tocilizumab) is representative of the majority of CAR-T experiences. The absence of ICANS is favorable and consistent with the patient's low baseline disease burden and ECOG 1 status at infusion. Total inpatient monitoring duration was 8 days, which is within the typical range of 6-10 days for CD19 CAR-T in DLBCL.
Response Assessment
Response in lymphoma is assessed using the Lugano classification, the standard framework referenced throughout the pivotal CAR-T trials. The Lugano classification provides the standardized criteria for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma.
Day 30 PET-CT
Interim PET-CT performed 30 days post-infusion showed complete metabolic response. All previously hypermetabolic lymph nodes demonstrated resolution of FDG uptake. Deauville score: 1 (no uptake above background). No new lesions identified. Per Lugano criteria, this constituted a complete response (CR) at the interim assessment — a clinically meaningful early indicator of treatment efficacy.
Day 90 PET-CT
Confirmatory PET-CT at day 90 post-infusion confirmed sustained complete metabolic response. Deauville score remained at 1. Bone marrow biopsy performed concurrently was negative for lymphoma involvement by morphology, immunohistochemistry, and flow cytometry. Minimal residual disease (MRD) assessment by next-generation sequencing (sensitivity 10⁻⁵) was negative. Per Lugano criteria, this confirmed complete remission (CR) with MRD negativity at day 90.
Outcome Significance
This patient's day-90 result — complete remission with MRD negativity by PET-CT and bone marrow under Lugano criteria — places him among the substantial subset of relapsed/refractory DLBCL patients who achieve durable response to CD19 CAR-T therapy. Across the pivotal registrational trials, axi-cel showed an objective response rate of 83% with a complete response rate of 58% in the ZUMA-1 trial after 27 months of follow-up, while tisa-cel showed a best overall response rate of 52%, with 40% complete response, in the JULIET trial. More broadly, the three approved CD19 CAR-T products have been shown to achieve durable, long-term disease-free survival in approximately 40% of treated patients with relapsed/refractory DLBCL.
What This Case Does and Does Not Show
This is one documented patient's outcome, not a guarantee or a typical result. Complete remission at day 90 is a meaningful, real, and clinically significant milestone — but it is not the same as long-term cure, and durability needs to be followed over months and years, not weeks.
What This Case Illustrates
- A patient who had exhausted three lines of standard therapy in the US — exactly the population CD19 CAR-T is designed for — was able to access CD19-directed CAR-T therapy
- The patient completed the full clinical pathway (staging, leukapheresis, conditioning, infusion, toxicity monitoring, and response assessment)
- The patient reached a confirmed complete remission by recognized international response criteria (Lugano) at a center outside the US
- Toxicity was managed according to established protocols with a favorable outcome
What This Case Does Not Show
- That outcomes in China are superior to US CAR-T centers — the response rates cited above from ZUMA-1 and JULIET are Western trial data, used here only as a reference point
- That this outcome is typical or guaranteed for every relapsed/refractory DLBCL patient
- Long-term durability beyond day 90 — that requires continued follow-up imaging at 6, 12, and 24 months, which should be reported as a future update to this case study
- A comparison of cost-effectiveness or quality-adjusted survival — those analyses require larger cohorts
Follow-Up Update (Pending)
At the time of publication, the patient is at month 6 post-infusion with ongoing complete remission. A 12-month and 24-month follow-up update will be added to this case study as dated appendices (not edits to the original timeline) to maintain a clear audit trail, once those milestones are reached and consent is reconfirmed.
Frequently Asked Questions
In this specific case, the patient faced a 14-week manufacturing waitlist at the nearest US CAR-T center, combined with an insurance prior-authorization denial that was still under appeal. With rapidly progressing DLBCL after 3 prior lines, the patient's oncologist supported seeking faster access through a partner center in Beijing that could complete leukapheresis within 10 days of referral. This is not representative of all US patients' experiences, but illustrates one documented access pathway.
China has both internationally licensed CAR-T products manufactured locally under license, and independently developed domestic CD19-directed CAR-T constructs. In this case, the patient received a domestically developed CD19 CAR-T construct that has published Phase II trial data in China showing comparable ORR and safety profiles to Western pivotal trials. The specific product name has been generalized to protect the treating institution's identity.
It means that on PET-CT imaging performed 90 days after CAR-T infusion, no evidence of active lymphoma was detected according to the Lugano classification, the internationally standardized criteria used to assess lymphoma response. It is an important and encouraging milestone, but ongoing monitoring is required to confirm the remission is durable over time. Complete remission is not equivalent to cure — long-term follow-up is essential.
The patient experienced Grade 2 Cytokine Release Syndrome (CRS) starting on day 3 post-infusion, with fever up to 38.9°C and transient hypotension. This was managed with two doses of tocilizumab and supportive IV fluids, and resolved within 24 hours. No ICANS (neurotoxicity) occurred. The patient also experienced Grade 3 neutropenia (ANC nadir 400/μL) managed with G-CSF. Total inpatient monitoring was 8 days. This toxicity profile is representative of the majority of CD19 CAR-T experiences in DLBCL.
No. Response to CD19 CAR-T therapy varies by patient, prior treatment history, disease burden at the time of infusion, and other clinical factors. This case illustrates one patient's documented path and outcome, not an expected result for every patient with similar disease history. Across pivotal trials, complete response rates range from 40-58% in relapsed/refractory DLBCL, meaning a substantial proportion of patients do not achieve CR. Patients should discuss their individual prognosis with their treating oncologist.